Kassahun Bekele Bezawit, Nebieridze Anano, Moses Daniel Itopa, Byiringiro Clever, Nazir Abubakar, Algawork Kibru Ermias, Wojtara Magda, Uwishema Olivier
Oli Health Magazine Organization, Research and Education, Kigali, Rwanda.
George Washington University, Milken Institute of Public Health, Washington, DC.
Ann Med Surg (Lond). 2023 Nov 20;86(1):624-627. doi: 10.1097/MS9.0000000000001536. eCollection 2024 Jan.
Epilepsy is the most widespread neurological disorder in Africa, affecting an estimated 25 million people. The disorder is characterized by recurrent seizures, which can be caused by a variety of factors, including past trauma, central nervous system infections, and genetic disorders. Diagnosis and treatment of epilepsy are challenging in African patients due to several factors, including the low socioeconomic status of the residents and limited access to appropriate medication. Phenobarbital remains the only drug widely available to patients, but it is not always effective and can have significant side effects. In addition to the medical challenges, individuals with epilepsy also face a lot of social stigmas in Africa. Widespread superstitions and false beliefs lead to prejudices against these people, making it difficult for them to live fulfilling social lives. With the development of new treatment modalities, such as gene therapy, stem cell therapy, and P-glycoprotein inhibitors, it is more important now than ever to increase the research output for the African region to create the best possible treatment and maximize patient outcomes.
癫痫是非洲最普遍的神经系统疾病,估计有2500万人受其影响。该疾病的特征是反复发作的癫痫,其可由多种因素引起,包括既往创伤、中枢神经系统感染和遗传疾病。由于多种因素,包括居民社会经济地位低下以及获得适当药物的机会有限,非洲患者的癫痫诊断和治疗具有挑战性。苯巴比妥仍然是患者唯一广泛可用的药物,但它并不总是有效,并且可能有显著的副作用。除了医疗挑战外,癫痫患者在非洲还面临许多社会耻辱。广泛存在的迷信和错误观念导致对这些人的偏见,使他们难以过上充实的社会生活。随着基因治疗、干细胞治疗和P-糖蛋白抑制剂等新治疗方式的发展,现在比以往任何时候都更需要增加非洲地区的研究产出,以创造最佳的治疗方法并使患者预后最大化。